A promising scientific discovery inside a university does not have to remain inside the laboratory.

The NIH Small Business Technology Transfer Grant, or Parent STTR, helps U.S. small businesses partner formally with nonprofit research institutions to turn scientific innovations into products capable of reaching the market.

The current opportunity is PA-27-102, covering the R41 and R42 activity codes.

The first submission cycle under the new announcement occurred in September 2026. The remaining deadlines are January 5 and April 5, 2027, at 5:00pm local time of the applicant organisation.

What Is the NIH STTR Programme?

STTR is designed specifically to encourage technology transfer between research institutions and commercial businesses.

The award itself goes to the small business, but the project must involve a formal collaboration with a qualifying nonprofit research institution, such as a university.

This makes STTR particularly useful where an innovation originated in academia but needs a company to develop, validate and commercialise it.

The programme supports:

• Phase I feasibility research;
• Phase II research and development;
• Fast-Track applications;
• Direct to Phase II applications.

How Is STTR Different from SBIR?

The most important difference is the required research partnership.

Under STTR, at least 40% of the research or analytical effort must be performed by the small business, while at least 30% must be performed by the single partnering research institution.

Unlike SBIR, the principal investigator may be primarily employed either by the small business or by the nonprofit research partner.

However, the small business remains the official applicant and recipient of the federal award.

STTR can therefore be especially valuable for university researchers who want to commercialise research without immediately leaving their academic institution.

How Much Funding Is Available?

The current general SBA guidelines are approximately $323,090 for Phase I and $2,153,927 for Phase II.

Individual NIH institutes can approve different limits.

Under the current parent announcement, examples include:

• NCI: $700,000 Phase I and $2.5 million Phase II;
• NHLBI: $400,000 and $3 million;
• NIA: up to $700,000 and $3 million for qualifying projects;
• NIAID: $700,000 and $3 million;
• NINDS: $700,000 and $3 million;
• NIDDK: $400,000 and $2.5 million.

Applicants should confirm the funding policy of the institute most closely aligned with their research before finalising the budget.

Who Can Apply?

Only U.S. small business concerns can serve as the applicant.

The business must generally have 500 or fewer employees and satisfy the federal ownership and operating requirements.

One important difference from SBIR is that small businesses majority-owned by multiple venture-capital operating companies, hedge funds or private-equity firms are not eligible for NIH STTR.

The collaborating research organisation must also meet the programme’s definition of an eligible nonprofit research institution or qualifying federally funded research and development centre.

Which Technologies Are Suitable?

STTR can support technologies across the NIH mission, including:

• Biotechnology;
• Medical devices;
• Diagnostics;
• Artificial intelligence;
• Drug discovery;
• Digital therapeutics;
• Biomarkers;
• Genomics;
• Neuroscience technologies;
• Infectious-disease solutions;
• Diabetes technologies;
• Cancer technologies.

The important requirement is that the project has a credible route from research towards a commercial product or service.

Clinical Trial Rules Require Extra Attention

The parent announcement is labelled “clinical trial optional,” but that does not mean every NIH institute accepts STTR clinical trials.

For example, under the current announcement, NIAID and NIDDK do not accept clinical trials through Parent STTR PA-27-102.

Founders should check institute-specific rules before designing a clinical project.

What Makes a Strong STTR Application?

The proposal should demonstrate why the business and research institution need each other.

Avoid presenting the company as merely an administrative vehicle created to obtain university funding.

Show what the commercial team contributes, what unique scientific resources the research institution provides, how intellectual property will be handled and how the technology will eventually reach customers or patients.

The collaboration should look like a genuine commercialisation partnership.

Application Deadlines

The next deadline is January 5, 2027.

The final scheduled submission date under PA-27-102 is April 5, 2027.

View the official NIH Parent STTR opportunity PA-27-102

For university-linked innovations, STTR provides something particularly valuable: a structured route for transforming scientific research into a company without forcing founders to choose between academia and commercialisation at the beginning.